Upgrade to SI Premium - Free Trial

Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy, 'High Ambitions, High Reward'

February 8, 2018 8:49 AM
Roth Capital initiates coverage on Conatus Pharmaceuticals (NASDAQ: CNAT) with a Buy rating and a price target of $20.00.Analyst Yasmeen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot New Coverage New Coverage